An unsolicited acquisition proposal for InMode (NASDAQ: INMD) has lapsed with no deal. The company remains independent. InMode manufactures RF microneedling platforms (Morpheus8, Morpheus8MAX) and monopolar RF devices (Forma, Forma Plus) used across aesthetic and surgical practices.
Business & M&A
InMode Takeover Bid Lapses—No Deal Reached
An unsolicited acquisition proposal for InMode has expired without a transaction.
1-YEAR MOVE
INMD
▲1.0%
| Ticker | Company | 1-year change |
|---|---|---|
| INMD | InMode Ltd. | +1.0% |
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
InMode remains independent after failed takeover bid.
The failed takeover attempt reflects broader M&A volatility in the aesthetic device sector. InMode has strong clinical adoption and recurring revenue from consumables, but valuation disagreement or strategic misalignment prevented a transaction. For practices, this means InMode stays focused on its core business—device innovation and consumable economics—rather than being absorbed into a larger conglomerate. The company's independence preserves its agility in product development and pricing strategy, though it also means no immediate access to a larger parent's capital or distribution network.
Source: original report ↗
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.